Sector News

Perrigo racks up more opposition to Mylan’s now-official hostile bid

September 14, 2015
Life sciences

It’s official: Mylan has taken its Perrigo buyout offer to the Irish company’s shareholders. But plenty of industry-watchers are still opposed to the idea.

The Dublin drugmaker has advised its investors to “take no action” regarding Mylan’s offer, which involves Perrigo shareholders netting $75 in cash and 2.3 Mylan share for each Perrigo share. The company’s board will assess the offer and make an official recommendation within the next 10 days, it said.

Perrigo has been opposed to the tie-up from the outset, and recently, one of its high-profile shareholders–former company vice chairman Mori Arkin–spoke out against it, too.

“Usually, when a good company is acquired, it is for a significant premium. In our case, it’s negligible, if at all,” he told Reuters, predicting that Perrigo’s stock–which currently sits at around $180–would trade at near $190 come early next year.

And they’re not alone in their thinking. Valuation is “currently the key factor that will likely preclude Perrigo shareholders from tendering their shares,” Citi analysts wrote in a note to clients last week, and it’s the implied valuation of Mylan’s bid that is “likely to constitute the primary hurdle to Perrigo shareholder support for the transaction.”

BMO Capital Markets analyst David Maris chimed in Thursday, too, writing to investors that “we believe Perrigo is better off without Mylan” because of Mylan’s too-low offer, skepticism in its ability to squeeze out costs, and its lack of experience in the OTC business that’s Perrigo’s bread and butter.

Regardless, Mylan’s execs are still confident they can get the job done. “The strategic logic behind this combination is abundantly clear,” CEO Heather Bresch said in a statement on Monday, with chairman Robert Coury adding that the company believes “the majority of Perrigo shareholders will support this full and compelling offer.”

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).